Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/topiramate in Overweight Comorbidities/obesity

N/AWithdrawnNCT05209997

Eurofarma Laboratorios S.A.

Overview

An observational, multicenter, national study with retrospective real-life data collection on the combined treatment of sibutramine and topiramate (off-label use) for the treatment of overweight with comorbidity(ies) or obesity. Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be included in the study.

Study Type

OBSERVATIONAL

Conditions

Overweight Obesity

Interventions

Source document data collectionOTHER

Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be colected in the study.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients * Both sexes * Diagnose of overweight with comorbidity(ies) or obesity * Treatment use of sibutramine combined with topiramate * Treatment prescription between 2011 and the beginning of the study Exclusion Criteria: * Use of topiramate for other condition besides overweight with comorbidity(ies) or obesity * Individual use of one of the medications (sibutramine or topiramate)

Locations (2)

Eurofarma Laboratórios S.A

São Paulo, São Paulo, Brazil

HC-FMUSP

São Paulo, São Paulo, Brazil

Outcomes

Primary Outcomes

The percentage of patients who achieved a weight loss greater than 5%

Identification of the percentage of patients who achieved a weight loss greater than 5% in relation to the initial body weight.

Time frame: 20 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.